Stage (next event)
Phase 1 Trial
Catalyst Info & Data Links
TITLE: Allogenic iNKTs as COVID-19 Phase 1 trial
WHAT IS THE NEXT CATALYST EVENT?
Phase 1 Readout
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
Mechanism of Action
MECHANISM OF ACTION
Invariant natural killer T cells (iNKT cells) are a unique cell type that combines features of two critical arms of the immune system, T cells (adaptive immunity) and NK cells (innate immunity), making them invaluable in combating diseases like COVID-19 and cancer. Data from preclinical models that bear similarities to SARS-COV-2 suggest that iNKT cell therapy has the potential to eliminate the COVID-19 virus, dampen harmful inflammation, and promote protection from reinfection.
Updated by MV
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See what the community is saying - click to see full post